Allen & Overy has advised private equity firm The Riverside Company (“Riverside”), headquartered in New York and Cleveland, on the sale of the hematology system specialist Diatron to a subsidiary of Stratec Biomedical AG. The parties have agreed not to disclose the purchase price.
 
Diatron designs and manufactures system solutions for hematology applications, as well as related consumables. In the past financial year, the company generated sales equivalent to around 34 million euro.

Statec Biomedical AG, headquartered in Birkenfeld, designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Shares in the company are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
The Allen & Overy team comprised partner Dr Astrid Krüger and senior associate Daniel Epe (both Corporate/M&A, Munich).

Furthermore, the team included partner Fabian Beullekens (Corporate, Luxembourg), Pierre Schleimer (ICM-Banking, Luxembourg) and Zoltán Lengyel (Corporate, Budapest), counsels Karoly Foti (Banking, Budapest), Christophe Balthazard (Corporate, Luxembourg) and Florent Trouiller (Tax, Luxembourg) as well as associates András Bajzik and Csilla Gyori (both Banking, Budapest), Melissa Rockens (ICM-Banking, Luxemburg), Franz Kerger (Tax, Luxembourg), Dr Gregor Janisch (Corporate, Munich), Yves Holle (Antitrust, Hamburg) and Mark Sorensen (Corporate, New York).